© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Everolimus stands as a synthetic derivative of sirolimus, classified under the mammalian target of rapamycin (mTOR) inhibitors. Developed for immunosuppressive purposes and as an anti-cancer agent, Everolimus has become a staple in both transplant medicine and oncology treatment regimens. It is not just another pharmaceutical compound—it marks a significant advancement in targeted cancer therapy and post-transplant care, shaping patient outcomes over the last two decades.
Everolimus features a layered molecular structure, with the chemical formula C53H83NO14 and a molar mass of 958.2 g/mol. Examining its physical dimensions and formula reveals a dense arrangement of carbon, hydrogen, nitrogen, and oxygen atoms that support its intended pharmacological action. It belongs firmly in the lactone class of macrolides, and this backbone allows for the compound’s targeted interactions with regulatory proteins inside cells. Its presence as both a large and structurally intricate molecule speaks strongly to its effectiveness and selectivity in a clinical setting. The detailed atomic connections—over 50 carbon atoms and more than a dozen oxygen atoms—grant Everolimus the ability to disrupt critical growth pathways in abnormal cells.
Manufacturers typically deliver Everolimus in the form of white to off-white crystalline powder. The crystals are fine and difficult to distinguish without a microscope, giving it a powdery or flake-like appearance to the naked eye. It can also be compressed into solid tablets, which remain stable at room temperature. Measuring its density, Everolimus falls within the range you expect for solid, non-metal organic molecules, with a specific gravity near 1.17 g/cm³ at 25°C. This density packs the powder densely into pharmaceutical capsules, allowing for low-volume yet high-potency formulations. In the laboratory, it displays moderate solubility in ethanol, methanol, and DMSO, but stays only sparingly soluble in water—making formulation for oral and injectable applications a technical challenge.
Pharmaceutical producers define precise specifications for Everolimus: high purity percentages (typically greater than 98%), controlled particle size for both powder and flake forms, and tight moisture limits to guard against degradation. The material as supplied resists oxidation and thermal breakdown below 100°C, making it robust for transportation and long-term storage. Pearls or granulated forms see little commercial demand, as the standard flake or fine powder is easier to compress for medical uses. Raw material sourced for Everolimus must meet GMP standards for trace contaminants, since even low-level impurities alter the safety profile in humans. Exacting requirements for purity and stability drive the design of every production batch—from solvent choice to crystallization process controls.
Like many potent pharmaceutical agents, Everolimus falls into a controlled-access category, requiring careful handling and storage. The compound acts as a hazardous substance upon inhalation or skin exposure in concentrated, unformulated states. Regulated as a cytostatic drug, lab technicians use nitrile gloves, protective masks, and eye shields during all stages of material handling. Air circulation in preparation rooms becomes a non-negotiable point, limiting the risk of accidental inhalation. Safety data sheets flag the inhalational and dermal toxicity, with risk statements on possible mutagenicity and reproductive impact from chronic exposure. Disposal methods follow strict chemical waste and biohazard protocols, avoiding any possibility of environmental contamination through sewage or landfill. In my years working in pharmaceutical regulation, I have seen cases where loose handling led to dangerous skin rashes and, in rare instances, acute toxicity—to say nothing of the occupational risk for those not properly trained or equipped.
Everolimus, recognized by global customs authorities, carries the HS Code 29349990 under pharmaceutical products—specifically heterocyclic compounds with nitrogen hetero-atom(s) only. This code not only determines duties, tariffs, and trade restrictions but also guides how countries monitor imports and exports of potentially hazardous or controlled drug precursors. Importers and exporters submit detailed declarations against this code to customs authorities in line with international conventions on pharmaceutical trade, making it traceable through the entire supply chain.
Demand for high-purity Everolimus continues to rise with new clinical studies launching and wider approvals for use in cancer and transplant settings. Manufacturing complexity and contamination risk form key challenges facing suppliers, as does the low tolerance for error in pharmaceutical-grade output. To reduce exposure risk, facilities might invest further in air filtration and sealed transfer systems. Increasing staff training—enforcing protocols for lab safety, disposal, and spill cleanup—goes a long way toward preventing accidental poisoning or environmental leaks. For those in early-stage R&D labs, better awareness and direct supervision save costly setbacks and tragic accidents. One area the industry continues to work on relates to water solubility; upgraded formulation chemistry—such as lipid-based carriers—helps improve bioavailability, meaning more stable dosing options and easier patient compliance. Finally, global harmonization of customs codes and clearer labeling requirements on shipping documents streamline regulatory checks and stop illicit diversion. As the use of Everolimus expands, both regulators and drug companies share responsibility for designing a safer chemical supply chain that puts patient and worker safety front and center.
